320 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-7807
Assistant Professor-Clinical, Hematology
I started at Ohio State 1-Aug-2006 as one of two physicians to see patients with plasma cell dyscrasias. I am an assistant professor in the division of hematology and since Oct-2012, I lead the section of plasma cell dyscrasias which includes two clinician investigators (Drs. Yvonne Efebera and Ashley Rosko), one physician scientist (Dr. Don Benson), and one PhD scientist (Dr. Flavia Pichiorri).
FOCUS: My emphasis is clinical and translational research in multiple myeloma, an incurable blood cancer with an average survival of 4-10 years. Over the last 7 years, we have grown and are now one of the largest myeloma programs in the nation with approximately 30 new patients each month, >100 autologous transplants each year, and a panel of >700 patients that we see in clinic. Over the last 4 years, we enrolled more patients than any other cancer center in the nation on the phase III Cancer and Leukemia Group B (CALGB) clinical trial 100001 (Autologous followed by allogeneic sibling transplant in myeloma), CALGB 100104 (Lenalidomide maintenance after autologous stem cell transplant), and the ongoing nationwide phase III BTM-CTN 0702 trial evaluating consolidation after autologous transplant. Nationally I am a member of the myeloma committees of the ALLIANCE cooperative group, Multiple Myeloma Research Consortium, and the Bone Marrow Transplant Clinical Trials Network.
CLINICAL RESEARCH DIRECTIONS: I have published results of high impact journals related to my role as a clinical investigator, but my goal is to work to lay the ground work and achieve vertical steps in the field. I am focused on 1) experimental therapeutics with first-in-man studies or agents with mechanisms never before tested within hematologic malignancies such as 2 phase 1 trials with AR-42 and Reolysin for which I am the principal investigator; 2) novel methods to study epidemiological questions and solve clinical trial accrual difficulties by creating a statewide myeloma registry; and 3) Develop new treatment modalities such as cell therapy procedures, e.g. the development of chimeric antigen receptor gene transfer strategies into natural killer cells, a technology I have patented with Dr. Jianhua Yu.
DEVELOPMENT OUTREACH TO SUPPORT RESEARCH: Multiple Myeloma Opportunities for Research & Education (MMORE) (www.mmore.org) is a 501(c)(3) that was established by Nancy Kaufmann in 2008 after her daughter Sarah was diagnosed at 22 y.o. Their mission is to support myeloma research that will prolong life, improve quality of life, and ultimately find a cure. MMORE has generously supported research at Ohio State University and annually has held two large fundraising events – a 5k run in June (moveMMORE) and a gala in February (celebrateMMORE). As of 12-Feb-2012, MMORE has invested $770,000 to support myeloma research. I am MMORE's primary contact with Ohio State and am largely responsible for their investment in OSU, although I couldn't be more lucky to be working with engaging colleagues as part of my section, including Drs. Benson, Efebera, Pichiorri, Dr. Rosko will soon be joining our section, and collaborating with Dr. Jinahua Yu
Bone marrow transplantation
|present||State of Ohio Medical License: State Medical Board of Ohio|
|2002 - present||Internal Medicine: American Board of Internal Medicine|
|2005 - present||Hematology: American Board of Internal Medicine|
|2006 - present||Ohio State Medical License: State Medical Board of Ohio|
|2006 - present||Oncology: American Board of Internal Medicine|
Clark JI, Hofmeister CC, Keedy V, Sosman JA.. "Renal Cell Carcinoma." In In Oncology: An evidence-based approach. -. New York, NY: Springer, November 2005.
|07/01/2006||Attending Physician (Arthur G. James Cancer Hospital, BMT Service)|
|07/01/2006||Attending Physician (Arthur G. James Cancer Hospital, Outpatient Myeloma Clinic)|
|07/01/2006||Attending Physician (Arthur G. James Cancer Hospital, Hematology 1 (Lymphoma & Myeloma))|
Phase 1 Clinical Trial of NPI-0052 in Patients with Relapsed or Relapsed/ Refractory Multiple Myeloma.
Toward a Genomic Understanding of Multiple Myeloma (Multiple Myeloma Research Consortium).
Multiple Myeloma Research Consortium (MMRC) Ancillary Tissue Collection Project.
Retrospective Case-Control Study of the Effect of Statin use on Clinical Response to Autologous Stem Cell Transplantation in Myeloma Patients.
A Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed or Refractory Multiple Myeloma.
Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma.
Immune Reconstitution after Autologous Hematopoietic Stem Cell Transplantation for High-Risk Lymphoma and Myeloma.
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia
|1995||B.S., Brown University|
|1999||M.D., The Ohio State University|
|2012||M.Public Hlth., The Ohio State University|
|2010 - present||Drug Therapy|
|2010 - present||Clinical Lymphoma & Myeloma|
|2010 - present||Clinical Cancer Research|
|2010 - present||Clinical Cancer Pharmacology|
|2010 - present||Journal of Clinical Oncology|
|2010 - present||Blood|
|2012 - present||Cancer Chemotherapy and Pharmacology|
|1996||Samuel J. Roessler Research Scholarship.|
|2002||Internal Medicine Senior Resident of the Year Award.|
|2004||Clinical Research Training Institute (CRTI). American Society of Hematology.|
|2009||Imagine MMORE Award. Multiple Myeloma Opportunities for Research and Education.|
|2011||Business First's Forty Under 40 Award.|
|2011||Early Career Achievement Award.|
Jagadeesh, JM;Hofmeister CC; Nelson, SD; Barria, E. "Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death.." Biomedical sciences instrumentation. Vol. 33, (January 1997.): 497-502.
Clark,J,I; Hofmeister,C; Choudhury,A; Matz,G; Collins,S; Bastian,R; Melian,E; Emami,B; Petruzzelli,G. "Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma." CANCER. Vol. 92, no. 9. (November 2001.): 2334-2340.
Hofmeister,C,C; Quinn,A; Cooke,K,R; Stiff,P; Nickoloff,B; Ferrara,J,LM. "Graft-versus-host disease of the skin: Life and death on the epidermal edge." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 10, no. 6. (June 2004.): 366-372.
Hofmeister,Craig,C; Stiff,Patrick,J. "Mucosal protection by cytokines.." Current hematology reports. Vol. 4, no. 6. (November 2005.): 446-453.
Scaglione,S; Hofmeister,C,C; Stiff,P. "Evaluation of pulmonary infiltrates in patients after stem cell transplantation." HEMATOLOGY. Vol. 10, no. 6. (December 2005.): 469-481.
Clark JI, Hofmeister CC, Keedy V, Sosman JA. "An evidence-based approach." Oncology. Vol. 0, (November 2005.): 0-387.
Hofmeister,CC; Czerlanis,C; Forsythe,S; Stiff,PJ. "Retrospective utility of bronchoscopy after hematopoietic stem cell transplant." Bone Marrow Transplantation. Vol. 38, no. 10. (November 2006.): 693-698.
Hofmeister,C,C; Zhang,J; Knight,K,L; Le,P; Stiff,P,J. "Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche." BONE MARROW TRANSPLANTATION. Vol. 39, no. 1. (January 2007.): 11-23.
Hofmeister,CC; Marinier,DE; Czerlanis,C; Stiff,PJ. "Clinical Utility of Autopsy after Hematopoietic Stem Cell Transplantation." Biology of Blood and Marrow Transplantation. Vol. 13, no. 1. (January 2007.): 26-30.
Hamadani,M; Martin,LL; Benson,DM; Copelan,EA; Devine,SM; Hofmeister,CC. "Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR.." Bone marrow transplantation. Vol. 39, no. 4. (February 2007.): 249-251.
Hamadani M, Hade E, Benson DM Jr, Hofmeister CC. "The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma." Biol Blood Marrow Transplant. Vol. 14, no. 3. (March 2008.): 351-352.
Liu,Q; Farley,KL; Johnson,AJ; Muthusamy,N; Hofmeister,CC; Blum,KA; Schaaf,LJ; Grever,MR; Byrd,JC; Dalton,JT; Phelps,MA. "Development and validation of a highly sensitive liquid chromatography/mass spectrometry simultaneous quantification of lenalidomide and flavopiridol in human plasma." The Drug Monit. Vol. 30, no. 5. (January 2008.): 620-627.
Hofmeister,CC; Jansak,B; Denlinger,N; Kraut,EH; Benson,DM; Farag,SS. "Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma." LEUKEMIA RESEARCH. Vol. 32, no. 8. (August 2008.): 1295-1298.
Hamadani,M; Hofmeister,CC; Jansak,B; Phillips,G; Elder,P; Blum,W; Penza,S; Lin,TS; Klisovic,RB; Marcucci,G; Farag,SS; Devine,SM. "Addition of infliximab to standard graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 14, no. 7. (July 2008.): 783-789.
Hamadani,M; Benson,DM; Hofmeister,C,C; Elder,P; Blum,W; Porcu,P; Garzon,R; Blum,KA; Lin,TS; Marcucci,G; Devine,SM. "Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 5. (May 2009.): 547-553.
Clark,JI; Eisner,RM; Hofmeister,CC; Norton,J; Thomas,S; Choudhury,A; Petruzzelli,G; Lathers,D; Young,MRI; Lau,A; Emami,B. "Phase I Adjuvant Radiation with Docetaxel in High-Risk Head and Neck Cancer." AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. Vol. 32, no. 4. (August 2009.): 396-400.
Hamadani,M; Blum,W; Phillips,G; Elder,P; Andritsos,LA; Hofmeister,CC; O'Donnell,L; Klisovic,RB; Penza,S; Garzon,R; Krugh,D; Lin,T; Bechtel,T; Benson,DM; Byrd,JC; Marcucci,G; Devine,SM. "Improved nonrelapse mortality and infection rate with lower dose antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 11. (November 2009.): 1422-1430.
Benson,DM; Panzner,K; Hamadani,M; Hofmeister,CC; Bakan,CE; Smith,MK; Elder,P; Krugh,D; O'Donnell,L; Devine,SM. "Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma." LEUKEMIA & LYMPHOMA. Vol. 51, no. 2. (February 2010.): 243-251.
Lucas,DM; Alinari,L; West,DA; Davis,ME; Edwards,RB; Johnson,AJ; Blum,KA; Hofmeister,CC; Freitas,MA; Parthun,MR; Wang,D; Lehman,A; Zhang,X; Jarjoura,D; Kulp,SK; Croce,CM; Grever,MR; Chen,C-S; Baiocchi,RA; Byrd,JC. "The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo." PLOS One. Vol. 5, no. 6. (June 2010.): e10941-.
Benson,DM; Bakan,CE; Mishra,A; Hofmeister,CC; Efebera,YA; Becknell,B; Baiocchi,RA; Zhang,J; Yu,J; Smith,MK; Greenfield,CN; Porcu,P; Devine,SM; Rotem-Yehudar,R; Lozanski,G; Byrd,JC; Caligiuri,MA. "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody." Blood. Vol. 116, no. 13. (September 2010.): 2286-2294.
Fonseca,R; Richardson,P; Giralt,S; Lonial,S; Rajkumar,SV; Stewart,AK; Bensinger,W; Somlo,G; Vescio,R; Mikhael,J; Reeder,C; Tiedemann,R; Tricot,G; Rifkin,R; Shaughnessy,J; Munshi,N; Raje,N; Ghobrial,I; Laubach,J; Schlossman,R; Treon,S; Mahindra,A; Avigan,D; Rosenblatt,J; Jagannath,S; Niesvizky,R; Landau,H; Chen-Kiang,S; Siegel,DS; Zimmerman,T; Mehta,J; Vesole,D; Rosen,S; Hofmeister,CC; Lacy,M; Dispenziere,A; Borrello,I; Hayman,SR; Kumar,S; Buadi,F; Dingli,D; Russell,S; Alsina,M; Fernandez,H; Roy,V; Pereira,D; Stadtmauer,E; Vaj,R; Jakubowiak,A; Lentzsch,S; Song,K; Bahlis,N; Trudel,S; Chen,C; Reece,D; Stewart,D; Singhal,S; Comenzo,R; Gertz,MA; Greipp,PR; Durie,B; Barlogie,B; Anderson,K; Dalton,W; Coleman,M; Novis,S; Kyle,RA. "Conflicts of interest, authorship, and disclosures in industry-related scientific publications." MAYO CLINIC PROCEEDINGS. Vol. 85, no. 2. (February 2010.): 197-199.
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmeister CC, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM. "Downregulation of P53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development." Cancer Cell. Vol. 18, (January 2010.): 367-.
Hofmeister,CC; Jin,M; Catalano,SR; Benson,DM; Wu,HM. "TTP disease course is independent of myeloma treatment and response." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 85, no. 4. (April 2010.): 304-306.
Hofmeister,CC; Yang,X; Pichiorri,F; Chen,P; Rozewski,DM; Johnson,AJ; Lee,S; Liu,Z; Garr,CL; Hade,EM; Ji,J; Schaaf,LJ; Benson,DM; Kraut,EH; Hicks,WJ; Chan,KK; Chen,C-S; Farag,SS; Grever,MR; Byrd,JC; Phelps,MA. "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-Glycoprotein." JOURNAL OF CLINICAL ONCOLOGY. Vol. 29, no. 25. (September 2011.): 3427-3434.
Hamadani,M; Craig,M; Phillips,GS; Abraham,J; Tse,W; Cumpston,A; Gibson,L; Remick,SC; Bunner,P; Leadmon,S; Elder,P; Hofmeister,CC; Penza,S; Efebera,YA; Andritsos,L; Garzon,R; Benson,DM; Blum,W; Devine,SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." HEMATOLOGICAL ONCOLOGY. Vol. 29, no. 4. (December 2011.): 202-210.
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. "Initial genome sequencing and analysis of multiple myeloma." Nature. Vol. 24, (March 2011.): 467-72.
Benson,DM; Bakan,CE; Zhang,S; Collins,SM; Liang,J; Srivastava,S; Hofmeister,CC; Efebera,YA; Andre,P; Romagne,F; Blery,M; Bonnafous,C; Zhang,J; Clever,D; Caligiuri,MA; Farag,SS. "IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect." BLOOD. Vol. 118, no. 24. (December 2011.): 6387-6391.
Jakubowiak,AJ; Griffith,KA; Reece,DE; Hofmeister,CC; Lonial,S; Zimmerman,TM; Campagnaro,EL; Schlossman,RL; Laubach,JP; Raje,NS; Anderson,T; Mietzel,MA; Harvey,CK; Wear,SM; Barrickman,JC; Tendler,CL; Esseltine,D-L; Kelley,SL; Kaminski,MS; Anderson,KC; Richardson,PG. "Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial." Blood. Vol. 118, no. 3. (July 2011.): 535-543.
Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr. "Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents." HEMATOLOGICAL ONCOLOGY. Vol. 30, no. 3. (September 2012.): 156-162.
Hofmeister,CC; Yang,X; Phelps,MA. "Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 3. (January 2012.): 341-342.
Hemminger,J; Satoskar,A; Brodsky,S,V; Calomeni,E; Nadasdy,GM; Kovach,P; Hofmeister,CC; Nadasdy,T. "Unique Pattern of Renal kappa Light Chain Amyloid Deposition With Histiocytic Transdifferentiation of Tubular Epithelial Cells." AMERICAN JOURNAL OF SURGICAL PATHOLOGY. Vol. 36, no. 8. (August 2012.): 1253-1257.
Bruce JT, Tran JM, Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KL. "Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. Vol. 12, no. 5. (October 2012.): 325-329.
Benson DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera YA, Tiollier J, Caligiuri MA, Farag SS. "A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.." Blood. Vol. 120, no. 22. (November 2012.): 4324-4333.
McCarthy,PL; Owzar,K; Hofmeister,CC; Hurd,DD; Hassoun,Hani; Richardson,Paul,G; Giralt,Sergio; Stadtmauer,Edward,A; Weisdorf,Daniel,J; Vij,Ravi; Moreb,Jan,S; Callander,Natalie,Scott; Van Besien,Koen; Gentile,Teresa; Isola,Luis; Maziarz,Richard,T; Gabriel,Don,A; Bashey,Asad; Landau,Heather; Martin,Thomas; Qazilbash,Muzaffar,H; Levitan,D; McClune,B; Schlossman,R; Hars,V; Postiglione,J; Jiang,C; Bennett,E; Barry,S; Bressler,L; Kelly,M; Seiler,M; Rosenbaum,C; Hari,P; Pasquini,MC; Horowitz,MM; Shea,TC; Devine,SM; Anderson,KC; Linker,C. "Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma." NEW ENGLAND JOURNAL OF MEDICINE. Vol. 366, no. 19. (May 2012.): 1770-1781.
Chu J, Deng Y, Benson DM Jr, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J. "CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance In Vitro and In Vivo anti-tumor activity against human multiple myeloma." Leukemia. Vol. pending, no. pending. (September 2013.): pending-.
Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. "Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease." Clin Pharmacokinet. Vol. 52 no.8, (August 2013.): 705-12.
Pichiorri,Flavia; Palmieri,Dario; De Luca,Luciana; Consiglio,Jessica; You,Jia; Rocci,Alberto; Talabere,Tiffany; Piovan,Claudia; Lagana,Alessandro; Cascione,Luciano; Guan,Jingwen; Gasparini,Pierluigi; Balatti,Veronica; Nuovo,Gerard; Coppola,Vincenzo; Hofmeister,Craig,C; Marcucci,Guido; Byrd,John,C; Volinia,Stefano; Shapiro,Charles,L; Freitas,Michael,A; Croce,Carlo,M. "In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation." journal of experimental medicine. Vol. 210, no. 5. (May 2013.): 951-968.
Clark JI, Greene JB, Lau Clark A, Dalal JS, Hofmeister CC. "Phase 1 pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer." Med Oncol. Vol. 30, no. 1. (March 2013.): 358-.
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. "Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma." Leuk Lymphoma. Vol. 54 no.8, (August 2013.): 1658-64.
|January 2003||Hofmeister CC, Forsythe S, Czerlanis C, Stiff P."Should bronchoscopies be routinely performed for post-transplant infiltrates?" San Diego, CA. : abstract #683|
|November 2005||Hofmeister CC, Parthasarathy M, Czerlanis C, Stiff PJ."Autopsies post hematopoietic stem cell transpalnt: a reassessment of their role in patient management." Washington DC. : abstract #1332|
|January 2009||Hofmeister CC, Richardson P, Zimmerman T, Spear MA, Palladino MA, Longenecker AM, Cropp GF, Lloyd GK, Hannah AL, Anderson K."Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refactory multiple myeloma (r/r MM)" Chicago. : Abstract #8505|
|December 2009||Richardson P, Hofmeister CC, Jakubowiak A, Zimmerman T, Spear M, Palladino M, Longenecker A, Kelly S, Neuteboom S, Cropp G, Lloyd K, Hannah A, Anderson K."Phase I trial of the novel structure Proteasome Inhibitor NPI-0052 in patients with relapsed and relapsed refractory multiple myeloma (MM)" Washington DC. : abstract #431|
|February 2009||Hamadani M, Benson D, Porcu P, Elder P, Andritsos A, Hofmeister CC, Garzon R, Lin T, Marcucci G, Blum W, Devine S."Evaluation of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA)" Philadelphia. : 5|
|February 2009||Benson D, Hofmeister CC, Hamadani M, Panzner K, Smith M, Penza S, Elder P, Krugh D, O'Donnell L, Devine D."Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide-based induction regimens" Washington DC. : 67|
|January 2009||Jakubowiak AJ, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach J, Raje NS, Anderson T, Griffith K, Hill M, harvey C, Dollard A, Wear S, Bock T, Tendler C, Esseltine DL, Kelley S, Kaminski MS, Anderson KC, Richardson PG."Lenalidomide, Bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial" Chicago. : abstract 8517|
|December 2009||Hofmeister CC, Benson D, Efebera Y, Farag S, Grever MR."Phase I trial of Lenalidomide and CCI-779 in patients with relapsed multiple myeloma" Washington DC. : abstract #2884|
|January 2009||Richardson P, Hofmeister CC, Zimmerman T, Chanan-Khan A, Spear M, Palladino M, Longenecker A, Cropp G, Lloyd K, Wear S, Hannah A, Anderson K."Phase I Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma" Chicago. : abstract #8505|
|January 2009||Pichiorri F, Sung-Suk S, Taccioli C, Hofmeister CC, Benson D, Kuehl M, Munker R, Huebner K, Aqeilan R, Croce C."Regulation of expression of multiple miRNAs defines the cellular response to non genotoxic p53 activation in multiple myeloma cells" Philadelphia. : abstract #2637|
|January 2009||Jakubowiak A, Hofmeister CC, Camagnaro E, Kendall T, Zimmerman T, Schlossman R, Reece D, Lonial S, Hari M, Hector-Word Z, Griffith K, Tendler C, Esseltine D, Bock T, Kaminski M, Dollard A, Kelly S, Adnerson K, Richardson P."Phase I/II trial of Lenalidomide, Bortezomib, Doxil and Dexamethasone in Frontline Multiple Myeloma (MM)" Washington DC. : abstract #132|
|December 2009||Pichiorri F, Suh S, De Luca L, Taccioli C, Benson D, Hofmeister CC, Ageilan R, Croce C."p53-Inducible micrornas 192 and 215 regulate p53 expression and IGF 1 Axis multiple myeloma" Washington DC. : abstract #1973|
|December 2009||McCarthy P, Owzar K, Stadtmauer E, Giralt S, Hurd H, Hassoun H, Hofmeister CC, Richardson P, Weisdorf D, Pasquini M, Hars V, Kelly M, Postiglione J, Sutherland S, Anderson K, Linker C."Phase III intergroup study of Lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events" Washington DC. : abstract #3416|
|December 2009||Benson D, Hofmeister CC, Padmanabhan S, Abonour R, Suvannasankha A, Mita A, Squiban P, Smith MK, Bakan C, Marzetto M, Andre P, Tollier J, Caligiuri M, Farag S."Novel monoclonal antibody enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Interm phase I trials results" Washington DC. : abstract #2880|
|December 2009||Benson D, Bakan C, Zhang S, Alghothani L, Liang J,Hofmeister CC, Srivastava S, Smith MK, Greenfield C, Andre P, Squiban P, Romagne F, Caligiuri M, Farag S."IPH2101, a novel anti-inhibitory KIR monoclonal antibody, and Lenalidomide combined to enhance the natural killer (NK) cell versus multiple myeloma (MM) effect" Washington DC. : abstract #4641|
|May 2009||Benson DM, Romagne P, Squiban N, Wagtmann N, Farag S, Mita A, Hofmeister CC, Smith M, Bakan C, Caligiuri M."Novel monoclonal antibody that enhances natural kill (NK) cell cytotoxicity against multiple myeloma (MM) preclinical data interim phase I clinical trial results" Chicago. : abstract #3032|
|November 2010||Jakubowiak A, Reece D, Hofmeister CC, Lonial S, Zimmerman T, Campagnaro E, Schlossman R, Laubach J, Raje N, Anderson T, Griffith K, Hill M, Harvey C, Wear S, Barrickman J, Tendler C, Esseltine D, Kelley S, Kaminiski M, Anderson K, Richardson P."Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in newly diagnosed Multiple Myeloma (MM): Final results of Phase I/II MMRC trial" Washington DC. : Abstract #1937|
|January 2010||McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA."Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104" Chicago. : abstract #8017|
|January 2010||Benson DM, Padmanabahn S, Hofmeister CC, Bakan C, Abonour R, Suvannasankha A, Efebera Y, Squiban P, Caligiuri MA, Farag SS."A Phase I trial of IPH2101, a novel anti-ihibitory KIR monoclonal antibody, in patient with multiple myeloma" Washington DC. : Abstract #8139|
|November 2010||Baiocchi R, Flynn J, Jones JA, Blum KA, Hofmeister CC, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor Dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients" Washington, DC. : Abstract #3966|
|November 2010||Wear S, Richardson P, Revta C, Vij R, Fiala M, Lonial S, Francis D, Siegel DS, Schramm A, Jakubowiak A, Harvey C, Reece D, Gul E, Jagannath S, La L, Hofmeister CC, Jansak B, Stewart K, Hagerty R, Wolf J, Davis B, Krishnan A, Duarte L, Zimmerman T, Cisneros A, Kumar S, Birgin A, Ott R, Tasca L, Kelley S, Anderson K, Giusti K."The Multiple Myeloma Research Consortium (MMRC) Model: Reduced time to trial activation and improved accrual metrics" Washington DC. : Abstract #3803|
|November 2010||Habib J, Dunavin N, Phillips G, Elder P, Tranovich M, Benson D, Hofmeister CC, Byrd JC, Devine SM, Efebera YA."Analysis of 179 patients with newly diagnosed Multiple Myeloma (MM) treated with novel agents followed by autologous stem cell transplantation (ASCT): a retrospective study." Washington DC. : abstract #1343|
|November 2010||Furman R, Eradat H, Switzky J, hayman S, Hofmeister CC, Avignon N, Leonard J, Coleman M, Liao Q, Shah D, Brownell-Buttich S, Lisby S, Lin TS."A Phase II trial of Ofatumumab in subjects with Waldenstrom's macroglobulinemia" Washington DC. : Abstract #1795|
|November 2010||Dunavin N, Habib J, Phillips G, Edler P, Tranovich M, Benson DM, Hofmeister CC, Byrd JC, Devine SM, Efebera YA."Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma" Washington DC. : Abstract #3564|
|November 2010||Benson DM, Bakan C, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera Y, Blanchet S, Caligiuri M, Farag S."IPH2101, a novel anti-inhibitory KIR monclonal antibody for multiple myeloma: Interm Phase I trial results and correlative biologic and safety data" Washington DC. : Abstract #1966|
|November 2010||McCarthy P, Owzar K, Anderson K, Hofmeister CC, Hurd D, Hassoun H, Giralt S, Stadtmauer E, Richardson P, Weisdorf D, Vij R, Moreb J, Callander N, Van Besien K, Gentile T, Isola L, Maziarz R, Gabriel D, Bashey A, Landau H, Martin T, Qazilbash M, Levitan D, McClune B, hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Horowitz M, Shea T, Devine S, Linker C."Phase III intergroup study of Lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104" Washington DC. : Abstract #37|
|November 2011||Richardson P, Spencer A, Cannell P, Harrison S, Catley L, Underhill C, Zimmerman T, Hofmeister CC, Jakubowiak A, Laubach J, Palladino M, Longenecker A, Lay A, Wear S, Lloyd K, Hannah A, Reich S, Spear M, Anderson K."Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)" Washington. : abstract #302|
|November 2011||Wear S, Richardson P, Revta C, Vij R, Fiala M, Lonial S, Mitchell A, Siegel D, Aleman A, Jakubowiak A, Durecki D, Reece D, Gul E, Chari A, Jagannath S, La L, Hofmeister CC, Bowers M, Stewart K, Hagerty R, Wolf J, Pelle-Day G, Krishnan A, Duarte L, Zimmerman T, Larsen D, Kumar S, Birgin A, Raje N, Roy V, Maharaj M, Fay J, Messing T, Ott R, Tasca L, Anderson K, and Giusti K.."The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development." Washington. : abstract #1024|
|November 2011||Richardson P, Siegel D, Vij R, Hofmeister CC, Jagannath S, Chen C, Lonial S, Jakubowiak J, Bahlis N, Baz R, Larkins G, Chen M, Zaki M, and Anderson K."Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results" Washington. : abstract #634|
|November 2011||Furman R, Eradat H, DiRienzo C, Hayman S, Hofmeister CC, Avignon N, Leonard J, Coleman M, Advani R, Switzky J, Liao Q, Shah D, Lisby S, Lin T."A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia." Washington. : abstract #3701|
|November 2012||Jagannath S, Hofmeister CC, Siegel DD, Vij R, Lonial S, Anderson KC, Chen M, Zaki M, Richardson PG.."Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) on Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis." Washington DC. : abstract #450|
|November 2012||Vij R, Hofmeister CC, Richardson PG, Jagannath S, Siegel DS, Baz R, Chen M, Zaki M, Larkins G, Anderson KC.."Pomalidomide (POM) with Low-Does Dexamethasone (LoDEX) in Patients with Relapsed Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure." Washington DC. : abstract #4070|
|November 2012||Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA.."Immunomodulation of Both Donors and recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." Washington DC. : abstract #1942|
|November 2012||Benson DM, Cohen AD, Munshi NC, Jagannath S, Spitzer G, Hofmeister CC, Zerbib R, Andre P, Efebera YA, Oxier S, Caligiuri MA.."A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results" Washington DC. : abstract #4058|
|November 2012||Richardson PG, Hofmeister CC, Siegel DS, Lonial S, Zaki M, Hua Y, Shah S, Wang J, Anderson KC.."MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma." Washington DC. : abstract #1949|
|November 2012||Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G.."Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." Washington DC. : abstract #1949|
|November 2012||Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA."The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma" Washington DC. : abstract #4286|
|November 2012||Hofmeister CC, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM, Andritsos LA, Greenfield CN, Sell M, Geyer S, Byrd JC, Grever MR.."Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma." Washington DC. : abstract #2955|
|November 2012||Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G.."Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." Washington DC. : abstract #4192|
|November 2012||Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Greenfield CN, Sell M, Earl CT, Zitesman J, Quinion C, Lustberg ME, Andritsos LA, Devine SM.."Post Autologous Transplant Vorinostat (SAHA) in Hish Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance." Washington, DC. : abstract #2004|
|November 2012||Stiff A, Rocci A, Hofmeister CC, Omede’ P, Geyer S, Bringhen S, Cascione L, Bingman A, Gambella M, Cavallo F, De Luca L, Guan J, Larocca A, Corry J, Gay F, Efebera YA, Croce UG, Palumbo A, Pichiorri F.."miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients." Washington DC. : abstract #2921|
|November 2012||Stewart AK, Vij R, Laubach JP, Hofmeister CC, Hagerty R, Dueck AC, Kumar SK.."Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma." Washington DC. : abstract #1859|
|November 2012||Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson DM, Greenfield CN, Sell M, Devine SM."Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma." Washington DC. : abstract #3114|
|March 2013||Hofmeister CC."Low Testosterone is associated with shorter PFS in Multiple Myeloma" Kyoto. : abstract #234|
|March 2013||Hofmeister CC."Serum miRNAs add to ISS and FISH to predict PFS and OS in phase 3 trial" Kyoto. : abstract #322|
|September 2007||Hofmeister, CC."OSU MedNet 21" The Ohio State University|
|November 2012||Hofmeister, CC."Ohio Myeloma Initiative" http://ohiomyeloma.org|
Hofmeister, CC, Benson DM. "Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis Registry." Filed January 2012.
Hofmeister, CC, Jianhua, Y, Jianhiong. "Chimeric Antigen Receptor (CAR) engineered natural killer cells for cancer immunotherapy." Ohio State University. Filed May 2013.
"Multiple Myeloma." Presented at Tumor Board Meeting, Upper Sandusky, Ohio. (August 2006)
"An Update on the Management of Multiple Myeloma." Presented at Oncology Best Practices, Columbus. (February 2007)
"An Update on the Management of Multiple Myeloma." Presented at Oncology Best Practices, Columbus, Ohio. (June 2007)
"Myeloma Management in 2007." Presented at Tumor Board Meeting, Mansfield, Ohio. (August 2007)
"Multiple Myeloma." Presented at Grand Rounds, Kettering Medical Center, Kettering, Ohio. (August 2007)
"Diagnosing and Treating Multiple Myeloma in 2008." Presented at Grand Rounds, Blanchard Valley Hospital. Findlay, Ohio. (June 2008)
"Diagnosing and Treating Multiple Myeloma in 2008." Presented at Grand Rounds, Mount Carmel West. Columbus, Ohio. (August 2008)
"An Update from ASH and the 12th Annual International Myeloma Workshop in Washington." Presented at American Society of Hematology, Washington. (August 2009)
"Stem Cell Transplantation in Multiple Myeloma." Presented at MMRF Institutional Insights in Multiple Myeloma Patients/Caregiver Symposium, Boston, Massachusetts. (August 2009)
"Supportive Care in Multiple Myeloma." Presented at MMRF Institutional Insights in Multiple Myeloma Patient/Caregiver Symposium, Chicago. (June 2009)
"Tailoring Treatment to the Individual Patient: Transplantation - Eligible Patients." Presented at CCO CME Activity, Bath, New York. (August 2010)
"Spanning the Continuum of Care: Optimizing Patient Outcomes in Multiple Myeloma.." Presented at Clinical Care Options CME Activity, Florida Hospital Medical Center. Daytona Beach, Florida. (August 2010)
"Multiple Myeloma in 2010." Presented at Leukemia and Lymphoma Society Patient Education Activity, Dayton, Ohio. (August 2010)
"Multiple Myeloma '10: Tailoring Treatment to Optimize Patient Outcomes." Presented at CCO CME Activity, Mansfield, Ohio. (August 2010)
"Multiple Myeloma Update 2010." Presented at MMRC Legal Roundtable, New York City, NY. (January 2010)
"Supportive Care." Presented at MMRF Patient Caregiver Symposium, New York City. (April 2010)
"Using AR-42 to better understand the mechanism of HDAC inhibition." Presented at Discovery on Target, Boston. (November 2010)
"Myeloma 2010: ASCO Update and Survival Advances." Presented at Grand Rounds, Huntington. (June 2010)
"Multiple Myeloma '10: Tailoring Treament to Optimize Patient Outcomes." Presented at CCO CME Activity, Dekalb. (January 2011)
"Multiple Myeloma '10: Tailoring Treatment to Optimize Patient Outcomes." Presented at CCO CME Activity, Madisonville. (January 2011)
A Patnaik, G Weiss, K Papadopoulos, C Hofmeister, R Tibes, A Tolcher, R Isaacs, J Jac, M Han, F Payumo, M Cotreau, R Ramanathan. A Phase I Study of Ficlatuzumab as Monotherapy or in Combination with Erlotinib in Patients with Refractory Advanced Solid Tumors and Multiple Myeloma. October 2013.
He S, Deng Y, Vasu S, Chu J, Shunzong Y, Zhang J, Zhijin F, Hofmeister C, He X, Henry M, Devine SM. FLT3L and AMD3100 Combination Increased Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcomes. July 2013.
Hofmeister, CC, Williams, N, Geyer, S, Hade, EM, Bowers, MA, Earl, CT, Quinion, C, Vaughn, J, Bingman, A, Humphries, K, Lozanski, G, Baiocchi, RA, Jaglowski, SM, Blum, K, Porcu, P, Flynn, J, Penza, S, Benson, DM, Andritsos, LA, Devine, SM. A Phase 1 study of Vorinostat Maintenance after Autologous Transplant in High Risk Lymphoma. October 2013.
Richardson, P; Siegel, D; Vig, R; Hofmeister, CC; Baz, R; Jagannath, S; Chen, C; Lonial, S; Jakubowiak, A; Bahlis, N; Song, K; Belch, A; Raje, N; Shustik, C; Lentzsch, S; Lacy, M; Mikhael, J; Matous, J; Vesole, D; Chen, M; Zaki, M; Jacques, C; Yu, Z; Anderson, K. Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma: Results of a Randomized Phase II Study. September 2013.
Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Hicks WJ, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. A phase I trial of Flavopiridol in relapsed multiple myeloma. August 2013.